Article
Efficacy, public health impact and optimal use of the Takeda dengue vaccine
2024-08-11
Abstract excerpt
Dengue is the most common arboviral infection, causing substantial morbidity and mortality globally. The licensing of Qdenga, a second-generation vaccine developed by Takeda Pharmaceuticals, is therefore timely, but the potential public health impact of vaccination across transmission settings needs to be evaluated. To address this, we characterised Qdenga’s efficacy profile using mathematical models calibrated to...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- aa6ab9b9-0904-52c9-9684-55976a418a11
- DOI
- 10.1101/2024.08.10.24311393